PaxVax' oral cholera vaccine succeeds in PhIII challenges

PaxVax' single-dose oral cholera vaccine candidate, PXVX0200, posted positive results in a pair of challenge studies, the company announced earlier this week. In patients challenged at 90 days after vaccination with cholera bacteria, the candidate proved 79.5% effective; in patients challenged at 10 days post-vaccination, it posted a 90.3% effectiveness rate. Release